Cybin IRL is a Canadian pharmaceutical company that is developing psychedelic drugs as medicines.[ 1] [ 2] [ 3]
The company's drug candidates include psilocybin (CYB001),[ 4] [ 5] CYB003 (deuterated psilocin ),[ 6] [ 7] [ 8] [ 9] CYB004 (deuterated dimethyltryptamine (DMT)),[ 10] CYB005 (deuterated phenethylamine derivative ),[ 11] [ 12] [ 13] [ 14] [ 15]
As of January 2025, CYB003 is in phase 3 clinical trials .[ 6] [ 7] Compass Pathways 's COMP360 (psilocybin) to have reached this late stage of clinical development.[ 16] [ 17]
In 2020, Cybin acquired psychedelic pharmaceutical company Adelia Therapeutics.[ 18]
See also
References
^ Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L (May 2021). "The Therapeutic Potential of Psilocybin" . Molecules . 26 (10): 2948. doi :10.3390/molecules26102948 PMC 8156539 PMID 34063505 . ^ Aday, Jacob S.; Barnett, Brian S.; Grossman, Dan; Murnane, Kevin S.; Nichols, Charles D.; Hendricks, Peter S. (1 September 2023). "Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry" . Psychedelic Medicine . 1 (3): 150– 165. doi :10.1089/psymed.2023.0013 . ISSN 2831-4425 . Cybin is currently launching a pilot study of a psilocybin analogue that may produce psychoactive effects for only 4 hours. ^ Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST (December 2023). "Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders" . Drug Discov Today . 28 (12): 103818. doi :10.1016/j.drudis.2023.103818 . PMID 37925136 . ^ "Psilocybin - Cybin - AdisInsight" . adisinsight.springer.com .^ "Delving into the Latest Updates on CYB-002 with Synapse" . Synapse . 23 January 2025. Retrieved 31 January 2025 .^ a b "CYB 003 - AdisInsight" . adisinsight.springer.com .^ a b "Delving into the Latest Updates on CYB-003 with Synapse" . synapse.patsnap.com .^ Palfreyman M, Krakowsky J, Morgan M, Canal C, Pathare P, Avery K, Reichelt A, Hartsel J, Nivorozhkin A, Inamder A, Varty G (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P361. In Vitro and In Vivo Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder" (PDF) . Neuropsychopharmacology . 47 (Suppl 1): 220–370 (271). doi :10.1038/s41386-022-01485-0 . PMC 9714399 PMID 36456694 . ^ Inamdar A, Morgan M, Krakowsky J, Reichelt A, Canal C, Mueller T, Avery K, Pathare P, Hartsel J, Nivorozhkin A, Varty G, Palfreyman M (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P362. Pharmacokinetic Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder" (PDF) . Neuropsychopharmacology . 47 (Suppl 1): 220–370 (271–272). doi :10.1038/s41386-022-01485-0 . PMC 9714399 PMID 36456694 . ^ "CYB 004 - AdisInsight" . adisinsight.springer.com .^ "CYB 005 - AdisInsight" . adisinsight.springer.com .^ "Delving into the Latest Updates on CYB-005 with Synapse" . synapse.patsnap.com .^ "| BioWorld" . www.bioworld.com .^ Psychedelic Alpha (29 June 2021). "Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement" . Psychedelic Alpha . Retrieved 31 January 2025 . ^ "Development Pipeline" . Cybin .^ Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nat Biotechnol . 42 (6): 827– 830. doi :10.1038/s41587-024-02285-1 . PMID 38831049 . ^ Michael Haichin (2024). "Psychedelics Drug Development Tracker" . Psychedelic Alpha . Retrieved 29 January 2025 . ^ Cybin Inc. (14 December 2020). "CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings" . GlobeNewswire News Room . Retrieved 6 February 2025 .
External links
